MDX 22
Alternative Names: Monoclonal antibody MDX 22Latest Information Update: 20 Aug 2002
At a glance
- Originator Medarex
- Class Monoclonal antibodies
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 20 Aug 2002 Discontinued - Phase-II for Acute myeloid leukaemia in USA (unspecified route)
- 28 Jul 1995 Phase-II clinical trials for Acute myeloid leukaemia in USA (Unknown route)